Clinical Trials Logo

Recurrent Childhood B-Lymphoblastic Lymphoma clinical trials

View clinical trials related to Recurrent Childhood B-Lymphoblastic Lymphoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01700946 Recruiting - Clinical trials for Recurrent Childhood B-Lymphoblastic Lymphoma

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

Start date: April 15, 2013
Phase: Phase 2
Study type: Interventional

The overall objective of this protocol is to improve the cure rate of relapsed precursor B-cell acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma. This phase II trial is studying risk-directed therapy for B-lymphoblastic leukemia or lymphoma in first relapse. Standard risk (SR) and high risk (HR) participants will receive different therapy. Treatment will consist of chemotherapy for SR participants, and chemotherapy followed by hematopoietic stem cell transplant (HSCT) for HR in first relapse. Induction therapy consists of three blocks of chemotherapy. The first block is a novel immunotherapy regimen that includes chemotherapy, rituximab and infusion of haploidentical natural killer (NK) cells. SR participants will continue to receive chemotherapy for a total duration of approximately 2 years. HR participants will be candidates for HSCT and will proceed to transplant once a suitable donor is found and their minimal residual disease (MRD) is negative.